Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Neurology

Subtypes and the Shift to Gene-Based Names

At a Glance

The diagnosis of congenital myopathy has shifted from relying on muscle biopsy appearances to identifying the exact gene mutation. Knowing the specific gene, like RYR1 or MTM1, is crucial for predicting symptom progression, avoiding anesthesia risks, and qualifying for new clinical trials.

For decades, congenital myopathies were named based on what a pathologist saw through a microscope during a muscle biopsy. While these names are still used today, the medical world has shifted to a much more precise system: gene-based classification. Understanding this shift is vital for navigating your child’s care and accessing the most modern treatments [1][2].

The Historical “Microscope” Names

In the past, if a doctor saw thread-like structures in a muscle sample, they called it Nemaline Myopathy. If they saw “holes” or “cores” in the center of muscle cells, they called it Central Core Disease. These names describe the symptoms of the muscle’s structure, but they don’t explain the cause [3][4].

The Modern Paradigm: Gene-First

Today, medical consensus has moved toward naming these conditions by the specific gene that has a mutation (pathogenic variant). We now know that many different genes can cause the same structural pattern under a microscope. Conversely, the same gene mutation can look different in different people [1][3][5].

Knowing the exact gene is now considered the “gold standard” because it:

  • Predicts Natural History: Some genes are associated with very stable physical strength, while others might mean we need to watch breathing or heart health more closely [6][7].
  • Ensures Safety: For example, knowing a child has an RYR1 mutation is critical for avoiding certain life-threatening anesthesia risks [8].
  • Opens Doors to Research: Clinical trials are increasingly “gene-specific,” meaning you can only participate if you know the exact molecular cause of the condition [9][10].

Linking the Old to the New

Below is a guide to how the historical names typically correspond to the most common genetic causes found today:

Historical Name Common Genetic Culprits What the Pathologist Saw
Nemaline Myopathy NEB, ACTA1, KLHL40, KBTBD13 Small, thread-like “rods” in the muscle fibers [11].
Core Myopathies RYR1, SEPN1 (SELENON) “Clear” areas (cores) where energy centers are missing [12].
Centronuclear Myopathy MTM1, DNM2, BIN1 The cell’s control center (nucleus) is in the middle instead of the edge [13].
Myotubular Myopathy MTM1 (X-linked) Muscle cells that look like immature “tubes” from fetal development [14].

Why This Matters for You

The shift to gene-based naming is an empowering change. It moves your child from a broad category (“muscle weakness”) to a specific molecular diagnosis (Personalized Medicine). This allows your medical team to focus on the exact protein that isn’t working correctly, leading to more tailored management and the potential for gene-targeted therapies in the future [6][15].

If your child’s diagnosis is still based solely on a biopsy from years ago, asking for Next-Generation Sequencing (NGS) is the recommended next step to find the specific genetic key to their condition [16][17].

Common questions in this guide

Why do doctors use gene names instead of older congenital myopathy names?
Doctors now prefer gene-based names because they provide a precise molecular cause for the disease. Knowing the exact gene mutation helps predict how the condition will progress, identifies specific health risks, and determines if a patient qualifies for targeted clinical trials.
How does knowing the specific gene mutation help my child's care?
Identifying the specific gene, such as RYR1 or SEPN1, allows for personalized medical care. It helps specialists anticipate breathing or heart issues, prevents life-threatening reactions to certain anesthesias, and provides clarity on the disease's expected progression.
What should I do if my child was diagnosed with a muscle biopsy years ago?
If your child's diagnosis relies solely on an older muscle biopsy, you should ask your neurologist or geneticist about Next-Generation Sequencing (NGS). This advanced genetic testing can pinpoint the exact gene mutation responsible for their specific type of congenital myopathy.
Should our family get tested if my child has a specific genetic mutation?
Once a specific gene mutation is identified, a genetic counselor can help determine if other family members should be tested. This is important for understanding inheritance patterns and potential risks for relatives, even if they currently have no symptoms.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Now that we have a genetic result, which 'historical' name would my child have been given in the past (e.g., Nemaline, Central Core)?
  2. 2.How does knowing the specific gene (e.g., RYR1 vs. SEPN1) change the way we monitor my child’s heart or breathing?
  3. 3.Is my child’s specific mutation associated with a known 'natural history' or typical progression?
  4. 4.Does this gene-based diagnosis qualify my child for any current or upcoming clinical trials?
  5. 5.Should other family members be tested for this specific gene mutation, even if they don't have symptoms?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Biallelic LINE insertion mutation in HACD1 causing congenital myopathy.

    Al Amrani F, Gorodetsky C, Hazrati LN, et al.

    Neurology. Genetics 2020; (6(3)):e423 doi:10.1212/NXG.0000000000000423.

    PMID: 32426512
  2. 2

    Congenital myopathies in adults: A diagnosis not to overlook.

    Pinto MJ, Passos BA, Grangeia A, et al.

    Acta neurologica Scandinavica 2022; (146(2)):152-159 doi:10.1111/ane.13632.

    PMID: 35548885
  3. 3

    Congenital myopathies: an update.

    Claeys KG

    Developmental medicine and child neurology 2020; (62(3)):297-302 doi:10.1111/dmcn.14365.

    PMID: 31578728
  4. 4

    Update on the Genetics of Congenital Myopathies.

    Pelin K, Wallgren-Pettersson C

    Seminars in pediatric neurology 2019; (29()):12-22 doi:10.1016/j.spen.2019.01.005.

    PMID: 31060721
  5. 5

    Myopathology in congenital myopathies.

    Sewry CA, Wallgren-Pettersson C

    Neuropathology and applied neurobiology 2017; (43(1)):5-23 doi:10.1111/nan.12369.

    PMID: 27976420
  6. 6

    Exome sequencing in undiagnosed congenital myopathy reveals new genes and refines genes-phenotypes correlations.

    de Feraudy Y, Vandroux M, Romero NB, et al.

    Genome medicine 2024; (16(1)):87 doi:10.1186/s13073-024-01353-0.

    PMID: 38982518
  7. 7

    Congenital Titinopathies Linked to Mutations in TTN Metatranscript-Only Exons.

    Perrin A, Garcia-Uzquiano R, Stojkovic T, et al.

    International journal of molecular sciences 2024; (25(23)) doi:10.3390/ijms252312994.

    PMID: 39684706
  8. 8

    Variant landscape of the RYR1 gene based on whole genome sequencing of the Singaporean population.

    Foo CTY, To YH, Irwanto A, et al.

    Scientific reports 2022; (12(1)):5429 doi:10.1038/s41598-022-09310-w.

    PMID: 35361824
  9. 9

    Myosin inhibition partially rescues the myofiber proteome in X-linked myotubular myopathy.

    Gerlach Melhedegaard E, Rostedt F, Gineste C, et al.

    JCI insight 2025; (10(24)).

    PMID: 41196692
  10. 10

    Aberrant regulation of epigenetic modifiers contributes to the pathogenesis in patients with selenoprotein N-related myopathies.

    Bachmann C, Noreen F, Voermans NC, et al.

    Human mutation 2019; (40(7)):962-974 doi:10.1002/humu.23745.

    PMID: 30932294
  11. 11

    Recent advances in nemaline myopathy.

    Laitila J, Wallgren-Pettersson C

    Neuromuscular disorders : NMD 2021; (31(10)):955-967 doi:10.1016/j.nmd.2021.07.012.

    PMID: 34561123
  12. 12

    Congenital myopathies: not only a paediatric topic.

    Jungbluth H, Voermans NC

    Current opinion in neurology 2016; (29(5)):642-50 doi:10.1097/WCO.0000000000000372.

    PMID: 27538056
  13. 13

    Phenotypic Spectrum of DNM2-Related Centronuclear Myopathy.

    Hayes LH, Perdomini M, Aykanat A, et al.

    Neurology. Genetics 2022; (8(6)):e200027 doi:10.1212/NXG.0000000000200027.

    PMID: 36324371
  14. 14

    A Study of a Cohort of X-Linked Myotubular Myopathy at the Clinical, Histologic, and Genetic Levels.

    Abath Neto O, Silva MR, Martins Cde A, et al.

    Pediatric neurology 2016; (58()):107-12.

    PMID: 26995067
  15. 15

    Genetic therapy for congenital myopathies.

    Maani N, Karolczak S, Dowling JJ

    Current opinion in neurology 2021; (34(5)):727-737 doi:10.1097/WCO.0000000000000978.

    PMID: 34267051
  16. 16

    Congenital myopathies.

    Younger DS

    Handbook of clinical neurology 2023; (195()):533-561 doi:10.1016/B978-0-323-98818-6.00027-3.

    PMID: 37562885
  17. 17

    [The MYOCAPTURE project: Capturing the elusive mutations behind congenital myopathies].

    de Feraudy Y, Laporte J

    Medecine sciences : M/S 2025; (41 Hors série n° 2()):64-70 doi:10.1051/medsci/2025180.

    PMID: 41313064

This page explains genetic subtypes of congenital myopathy for educational purposes only. Always consult a pediatric neurologist or genetic counselor for your child's specific diagnosis and testing needs.

Get notified when new evidence is published on Congenital myopathy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.